Esketamine Treatment Working Capital for Practices
Planning esketamine treatment working capital is one of the most practical steps for a psychiatry or behavioral health practice that wants to offer this service. Esketamine nasal spray is dispensed through a restricted safety program that requires certified treatment settings and in-office patient monitoring after each dose. Practices that participate may need to purchase medication in advance, set aside monitoring space and staff time, and wait for payer reimbursement.
That combination can place real pressure on cash flow, even when patient demand is strong. This guide explains where the cash goes and how working capital financing may help. It does not address which patients are appropriate for treatment. Program certification, prescribing, billing and coverage rules vary by payer and change over time, and nothing here is legal, clinical, billing or compliance advice; work with qualified billing and compliance professionals.
Why Esketamine Programs Strain Cash Flow
Many practices obtain esketamine through a buy-and-bill model, in which the practice purchases the drug, administers it in the office and then bills the payer. Others may work with specialty pharmacies, depending on payer requirements. Under buy-and-bill, the practice can carry medication costs for weeks or longer before collecting.
Other pressures include:
- Monitoring time: each session includes an observation period, so rooms and staff are occupied longer than for a typical medication visit
- Prior authorization: payers may require approval before treatment, adding administrative work and potential delays
- Treatment schedules: induction phases involve frequent visits, creating a concentrated period of drug and staffing costs
- Claim denials: documentation gaps or authorization issues can delay or reduce payment
- Inventory management: drug on hand ties up cash and must be tracked carefully
Estimating Esketamine Treatment Working Capital Needs
Every practice’s numbers will differ, but the planning approach is similar. Owners can work with their accountant to estimate:
- Medication purchase costs for the expected number of patients during induction and maintenance
- Staffing costs for monitoring and administrative support
- The typical time between administering treatment and receiving payment from each payer
- Expected denial and write-off patterns, based on early experience
- A reserve for slower-than-expected collections or patient growth
The goal is to understand the peak amount of cash tied up in the program at any one time. That figure, rather than annual revenue, drives how much working capital the practice may need. Our article on how much working capital a behavioral health practice needs covers the broader framework.
Space and Staffing Requirements
Because patients must remain under observation after each dose, practices need appropriate rooms and trained staff available throughout the monitoring period. Some practices remodel underused space or convert offices into treatment rooms. Others schedule sessions in blocks to manage staff time.
These changes may require modest build-out or furniture investment in addition to working capital. If the program is part of a larger growth plan, behavioral health expansion financing may help fund space improvements.
Payer Mix Matters
Coverage and reimbursement for esketamine treatment differ across commercial insurers, Medicare and Medicaid. Practices with heavy Medicaid exposure may face different authorization requirements and payment timing than practices serving mostly commercially insured patients.
Lenders reviewing a working capital request will look at payer mix and collection history. Our article on Medicaid exposure and behavioral health loans explains how lenders may view government payer concentration, and our guide to how lenders evaluate behavioral health practice cash flow covers the broader review.
Working Capital Financing Options
Depending on the practice’s history and needs, options may include:
- Revolving lines of credit: draw funds for drug purchases and payroll, then repay as claims are collected
- Working capital term loans: a fixed amount for launching the program and building reserves
- SBA-backed working capital: available in some cases, subject to program rules and lender review
Our working capital solutions page outlines how these tools differ. Lenders generally review historical financial statements, accounts receivable aging, payer mix, existing debt and the owners’ credit. Eligibility and terms depend on the business, the borrower, the use of proceeds, program rules and lender review. Every loan is subject to approval, and nothing here is a commitment to lend.
Operational Practices That Support Cash Flow
Financing works best alongside strong operations. Practices may benefit from:
- Verifying benefits and obtaining authorization before ordering drug for a patient
- Tracking inventory against scheduled sessions
- Monitoring claims and following up on denials promptly
- Reviewing program results regularly to adjust staffing and schedules
Billing and documentation processes should be set up and reviewed by qualified billing or compliance professionals.
Questions to Answer Before Launch
- Which payers in your market cover esketamine treatment, and what do they require?
- Will you purchase drug directly, use a specialty pharmacy or both?
- How many monitoring slots can your space and staff support each day?
- How will the program affect scheduling for your existing patients?
- What reserve will you keep if collections take longer than planned?
Answering these questions with your team, accountant and billing professionals can make your financing request more precise.
Esketamine Compared With Ketamine Clinics
Esketamine programs and ketamine infusion clinics are sometimes discussed together, but their business models differ. Ketamine clinics often operate on a cash-pay basis, while esketamine treatment is more often billed to insurance and involves drug purchasing and payer authorization. Our article on ketamine clinic startup cost and financing covers that model.
Final Thoughts
Esketamine treatment working capital needs come from the gap between paying for medication, staff and space and collecting from payers. Estimating the peak cash requirement, understanding payer mix and arranging appropriate financing before launch can help a practice offer this service without straining day-to-day operations.
US Medical Funding helps behavioral health practices access working capital and finance new service lines. Learn more about our behavioral health practice working capital options.
